Business Description
Innoviva Inc
NAICS : 325412
SIC : 2834
ISIN : US45781M1018
Share Class Description:
INVA: Ordinary SharesTotal Employee Number:
159Description
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.27 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | 0.42 | |||||
Interest Coverage | 9.21 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.16 | |||||
Beneish M-Score | -2.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.7 | |||||
3-Year EBITDA Growth Rate | 10.5 | |||||
3-Year EPS without NRI Growth Rate | 113.5 | |||||
3-Year FCF Growth Rate | 1.3 | |||||
3-Year Book Growth Rate | 24.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -18.16 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.77 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.26 | |||||
9-Day RSI | 43.37 | |||||
14-Day RSI | 46.03 | |||||
3-1 Month Momentum % | -7.13 | |||||
6-1 Month Momentum % | 7.45 | |||||
12-1 Month Momentum % | 10.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.13 | |||||
Quick Ratio | 20.07 | |||||
Cash Ratio | 16.74 | |||||
Days Inventory | 212.3 | |||||
Days Sales Outstanding | 23.73 | |||||
Days Payable | 28.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | 9.8 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.09 | |||||
Operating Margin % | 38.15 | |||||
Net Margin % | 119.89 | |||||
EBITDA Margin % | 153.03 | |||||
FCF Margin % | 43.52 | |||||
OCF Margin % | 43.64 | |||||
ROE % | 51.61 | |||||
ROA % | 33.67 | |||||
ROIC % | 13.88 | |||||
3-Year ROIIC % | -18.6 | |||||
ROC (Joel Greenblatt) % | 1194.84 | |||||
ROCE % | 44.92 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.71 | |||||
Forward PE Ratio | 5.6 | |||||
PE Ratio without NRI | 4.63 | |||||
Shiller PE Ratio | 8.99 | |||||
Price-to-Owner-Earnings | 3.31 | |||||
PS Ratio | 4.5 | |||||
PB Ratio | 1.23 | |||||
Price-to-Tangible-Book | 1.43 | |||||
Price-to-Free-Cash-Flow | 10.35 | |||||
Price-to-Operating-Cash-Flow | 10.32 | |||||
EV-to-EBIT | 2.11 | |||||
EV-to-EBITDA | 2.03 | |||||
EV-to-Revenue | 3.1 | |||||
EV-to-Forward-Revenue | 2.99 | |||||
EV-to-FCF | 7.12 | |||||
Price-to-GF-Value | 1.09 | |||||
Price-to-Projected-FCF | 0.53 | |||||
Price-to-Median-PS-Value | 0.99 | |||||
Price-to-Graham-Number | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 5.94 | |||||
| Price-to-Net-Cash | 14.02 | |||||
Earnings Yield (Greenblatt) % | 47.39 | |||||
FCF Yield % | 11.12 | |||||
Forward Rate of Return (Yacktman) % | -2.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INVA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Innoviva Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 420.69 | ||
| EPS (TTM) ($) | 6.01 | ||
| Beta | 0.1418 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.03 | ||
| Volatility % | 34.33 | ||
| 14-Day RSI | 46.03 | ||
| 14-Day ATR ($) | 0.672207 | ||
| 20-Day SMA ($) | 22.7365 | ||
| 12-1 Month Momentum % | 10.05 | ||
| 52-Week Range ($) | 16.52 - 25.145 | ||
| Shares Outstanding (Mil) | 73.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Innoviva Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Innoviva Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 33 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 13:20 | 22.52 (+0.27%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 22.65 (-1.65%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 10:00 | 24.24 (+3.46%) | ||
| Annual report for 2025 | 2026-02-25 | 23.42 (+0.21%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 23.42 (+0.21%) | ||
| 37th Annual Piper Sandler Healthcare Conference | 2025-12-02 16:30 | 21.16 (-2.17%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 18.15 (+0.50%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 13:00 | 20.48 (-2.20%) |
Show
Entries
Innoviva Inc Frequently Asked Questions
What is Innoviva Inc(INVA)'s stock price today?
The current price of INVA is $22.31. The 52 week high of INVA is $25.15 and 52 week low is $16.52.
When is next earnings date of Innoviva Inc(INVA)?
The next earnings date of Innoviva Inc(INVA) is 2026-08-06 Est..
Does Innoviva Inc(INVA) pay dividends? If so, how much?
Innoviva Inc(INVA) does not pay dividend.
Guru Commentaries on NAS:INVA
No articles.
Press Release
Articles on Innoviva Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers